{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:05:36Z","timestamp":1790791536473,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.ygyno.2013.03.002","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T08:47:00Z","timestamp":1362559620000},"page":"452-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer"],"prefix":"10.1016","volume":"129","clinical-trial-number":[{"clinical-trial-number":"nct00318370","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Deborah K.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2013.03.002_bb0005","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.ygyno.2013.03.002_bb0010","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/cncr.23425","article-title":"Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2013.03.002_bb0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/(SICI)1097-4644(19970615)65:4<479::AID-JCB4>3.0.CO;2-L","article-title":"Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines","volume":"65","author":"Miotti","year":"1997","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.ygyno.2013.03.002_bb0020","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1006\/gyno.2002.6705","article-title":"A step further in understanding the biology of the folate receptor in ovarian carcinoma","volume":"88","author":"Bagnoli","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0025","first-page":"5791","article-title":"Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH\/3T3 cells increases cell growth in vitro and in vivo","volume":"53","author":"Bottero","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F","article-title":"Overexpression of folate binding protein in ovarian cancers","volume":"74","author":"Toffoli","year":"1997","journal-title":"Int J Cancer (Pred Oncol)"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0035","first-page":"6","article-title":"Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha","volume":"7","author":"Ebel","year":"2007","journal-title":"Cancer Immun"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00280-012-1890-2","article-title":"Farletuzumab, an anti-folate receptor \u03b1 antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro","volume":"70","author":"Kamen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0155","first-page":"S135","article-title":"Therapeutic efficacy of folate receptor \u03b1 blockade with MORAb-003 in ovarian cancer","volume":"108","author":"Spannuth","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.03.002_bb0050","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/14712591003592069","article-title":"Farletuzumab in epithelial ovarian cancer","volume":"10","author":"Spannuth","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"21","key":"10.1016\/j.ygyno.2013.03.002_bb0055","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/1078-0432.CCR-10-0700","article-title":"Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study","volume":"16","author":"Konner","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ygyno.2013.03.002_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines)","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.nucmedbio.2007.12.008","article-title":"Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003","volume":"35","author":"Smith-Jones","year":"2008","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0070","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0075","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2013.03.002_bb0160","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) [correspondence]","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1634\/theoncologist.7-5-437","article-title":"CA125 response; can it replace traditional response criteria in ovarian cancer?","volume":"7","author":"Guppy","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0090","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1002\/cncr.25480","article-title":"Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis","volume":"116","author":"Moore","year":"2010","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.ygyno.2013.03.002_bb0095","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ygyno.2013.03.002_bb0100","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.03.002_bb0105","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/bjc.2011.364","article-title":"Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer","volume":"105","author":"Lee","year":"2011","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2013.03.002_bb0110","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the Binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"282","key":"10.1016\/j.ygyno.2013.03.002_bb0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimations from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.ygyno.2013.03.002_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"issue":"9375","key":"10.1016\/j.ygyno.2013.03.002_bb0125","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.ygyno.2013.03.002_bb0130","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.03.002_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/gyno.2001.6151","article-title":"Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer","volume":"81","author":"Bolis","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2013.03.002_bb0140","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mdi147","article-title":"Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study","volume":"16","author":"Gonzalez-Martin","year":"2005","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.03.002_bb0145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2007.05.008","article-title":"Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials","volume":"106","author":"Harrison","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2013.03.002_bb0150","first-page":"222","article-title":"Angiogenesis inhibitors: current strategies and future prospects","volume":"60","author":"Cook","year":"2010","journal-title":"CA Cancer J Clin"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:32:34Z","timestamp":1758771154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0090825813001509"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.03.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}